Creating a Robust Donor Ecosystem to Accelerate Patient Access to Cell and Gene Therapies
April 26, 2023The possibility of allogeneic “off-the-shelf” engineered T cell therapies as an alternative to overcome the limitations of autologous therapies has long been a goal for the industry, with some of […]
The Crucial Role of HLA Typing in Donor Selection for Cell and Gene Therapies
March 28, 2023The Human Leukocyte Antigens (HLA) are surface proteins on our cells and tissues serving as a mechanism for the body to distinguish between self and non-self, so our immune system […]
FAQ Blog Series: What’s the Difference between Positive and Negative Immunomagnetic Cell Separation?
March 14, 2023The simplicity and speed of immunomagnetic cell separation has made it the go-to method for isolating target cell populations since it was pioneered in 1990 by Miltenyi Biotec. The ability […]
AllCells Celebrates Women’s History Month
March 10, 2023Women’s History Month is celebrated every year in March to recognize and honor the contributions and achievements of women throughout history. The 2023 National Women’s History theme is “Celebrating Women […]
The World’s Largest Apheresis Network Serves as a Catalyst to Advance Cell and Gene Therapies
February 27, 2023Is The Industry Prepared for Another Year of Rapid Growth? The cell and gene therapy (CGT) industry is expected to grow rapidly for the next 10 years with an increasing […]
Navigating the complex world of regulations: How AllCells is changing cell therapy and protecting against product-ending events
February 23, 2023The cell therapy market is valued at 15 billion dollars and is set to double in value by 2030. Cell therapy has been instrumental in the development of treatments like […]
Better Together: Discovery Life Sciences and AllCells Join Forces
January 30, 2023In July of 2022, AllCells was acquired by Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists™. By combining over 30 years of cell and gene therapy (CGT) expertise, our […]
How AllCells’ Expanded Donor Collection Facilities Help You to Recruit the Right Donors and Scale Your Cell and Gene Therapy Development
November 7, 2022Unlike classical therapeutics (i.e., monoclonal antibodies), the raw starting materials for cell and gene therapies (CGTs) are derived from patient or donor cells. As such, these sources are not mass-produced […]
The Key to Developing Good Manufacturing Practice (GMP) Biomaterials for Cell and Gene Therapy Development
October 3, 2022A decade ago, the emergence of new immunotherapies in the cell and gene therapy (CGT) space opened up new avenues to treat disease, sparking excitement across the industry. However, the […]
Overcoming the Global Biomaterial Supply Chain Challenge for the Development of CAR-T Therapies
September 21, 2022By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is […]
